Literature DB >> 23243262

Clinical risk predictors for cerebral hyperperfusion syndrome after carotid endarterectomy.

Matthew B Maas1, Christopher J Kwolek, Joshua A Hirsch, Michael R Jaff, Guy A Rordorf.   

Abstract

BACKGROUND: Cerebral hyperperfusion syndrome (CHS) is an important complication of carotid endarterectomy (CEA), yet prior research has been limited to small cohorts and retrospective analyses, or studies using radiographic rather than clinical definitions.
METHODS: A prospective monitoring system was implemented to monitor CEA outcomes at a major academic medical centre. Independent, trained monitors from the neurology department examined all patients undergoing CEA preoperatively and postoperatively at 24 h and 30 days. Clinical variables were analysed to identify risk factors for CHS, which was defined as cases with postoperative development of a severe headache, new neurological deficits without infarction, seizure or intracerebral haemorrhage.
RESULTS: Between 2008 and 2010, 841 CEAs were monitored and CHS occurred in 14 (1.7%) subjects, including seizures in 5 (0.6%) and intracerebral haemorrhage in 4 (0.5%). Univariate analysis identified a history of dyslipidaemia, coronary artery disease, diastolic blood pressure, intraoperative shunt use and non-elective CEA (performed during hospitalisation for a symptomatic ipsilateral stroke, transient ischaemic attack or amaurosis fugax) as potential risks for CHS (all p≤0.15); other variables-including the degree of ipsilateral and contralateral stenosis, operative time, intraoperative EEG slowing, history of prior CEA or carotid stent and time from prior carotid interventions- were not significant. Logistic regression confirmed the risk association between non-elective CEA and CHS (p=0.046).
CONCLUSIONS: Independent, prospective monitoring of a large cohort of CEA cases identified a brief time interval between ischaemic symptoms and endarterectomy as the clearest risk factor for CHS.

Entities:  

Mesh:

Year:  2012        PMID: 23243262     DOI: 10.1136/jnnp-2012-303659

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  Insight into the cerebral hyperperfusion syndrome following carotid endarterectomy from the national Vascular Quality Initiative.

Authors:  Grace J Wang; Adam W Beck; Randall R DeMartino; Philip P Goodney; Caron B Rockman; Ronald M Fairman
Journal:  J Vasc Surg       Date:  2016-10-01       Impact factor: 4.268

Review 2.  Cerebral Hyperperfusion Syndrome After Carotid Revascularization and Acute Ischemic Stroke.

Authors:  Kathryn F Kirchoff-Torres; Ekaterina Bakradze
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

3.  Cortical non-aneurysmal subarachnoid hemorrhage post-carotid endarterectomy: a case report and literature review.

Authors:  Gopiga Thanabalasundaram; Silvia Hernández-Durán; Thabele Leslie-Mazwi; Christopher S Ogilvy
Journal:  Springerplus       Date:  2013-10-29

4.  Therapeutic strategy of severe circular calcified carotid plaque with hemodynamic impairment: A patient treated by carotid endarterectomy following balloon angioplasty to prevent hyperperfusion.

Authors:  Takaki Marutani; Daina Kashiwazaki; Shusuke Yamamoto; Naoki Akioka; Emiko Hori; Satoshi Kuroda
Journal:  Surg Neurol Int       Date:  2022-08-12

5.  Predicting Cerebral Hyperperfusion Syndrome Following Superficial Temporal Artery to Middle Cerebral Artery Bypass based on Intraoperative Perfusion-Weighted Magnetic Resonance Imaging.

Authors:  Defeng Wang; Fengping Zhu; Ka Ming Fung; Wei Zhu; Yishan Luo; Winnie Chiu Wing Chu; Vincent Chung Tong Mok; Jinsong Wu; Lin Shi; Anil T Ahuja; Ying Mao
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

6.  Post-carotid endarterectomy cerebral hyperperfusion syndrome : is it preventable by strict blood pressure control?

Authors:  Kyung Hyun Kim; Chang-Hyun Lee; Young-Je Son; Hee-Jin Yang; Young Sub Chung; Sang Hyung Lee
Journal:  J Korean Neurosurg Soc       Date:  2013-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.